-
The Journal of Surgical Research Jan 1977
Topics: Adolescent; Adrenal Gland Neoplasms; Adult; Blood Volume; Humans; Middle Aged; Norepinephrine; Phenoxybenzamine; Pheochromocytoma; Preoperative Care
PubMed: 834033
DOI: 10.1016/0022-4804(77)90125-1 -
Annals of Cardiac Anaesthesia 2015
Topics: Adrenergic alpha-Agonists; Cardiac Surgical Procedures; Humans; Hypotension; Perioperative Care; Phenoxybenzamine; Tachycardia
PubMed: 26440247
DOI: 10.4103/0971-9784.166473 -
The New England Journal of Medicine Apr 1971
Topics: Adult; Antibody Formation; Carcinogens; Humans; Immunosuppressive Agents; Phenoxybenzamine
PubMed: 5548043
DOI: 10.1056/NEJM197104082841420 -
Tumour Biology : the Journal of the... Mar 2016Phenoxybenzamine hydrochloride (PHEN) is a selective antagonist of both α-adrenoceptor and calmodulin that exhibits anticancer properties. The aim of this study was to...
Phenoxybenzamine hydrochloride (PHEN) is a selective antagonist of both α-adrenoceptor and calmodulin that exhibits anticancer properties. The aim of this study was to explore the anti-tumor function of PHEN in glioma. Cell proliferation assay was used to assess glioma cell growth. Migration and invasion capacity of glioma cells was monitored by wound-healing and transwell assay, respectively. Neurosphere formation test was adopted for the tumorigenesis of glioma cells, which was also confirmed by soft agar cloning formation test in vitro and a nude mouse model in vivo. Finally, we explored the potential pathway utilized by PHEN using Western blot and immunofluoresce staining. PHEN exhibited a significant inhibitory effect on the proliferation of both U251 and U87MG glioma cell lines in a positive dose-dependent manner. PHEN apparently attenuated the malignancy of glioma in terms of migration and invasion and also suppressed the tumorigenic capacity both in vitro and in vivo. Mechanism study showed that PHEN promoted tumor suppression by inhibiting the TrkB-Akt pathway. The results of the present study demonstrated that PHEN suppressed the proliferation, migration, invasion, and tumorigenesis of glioma cells, induced LINGO-1 expression, and inhibited the TrkB-Akt pathway, which may prove to be the mechanisms underlying the anti-tumor effect of PHEN on glioma cells.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Cell Proliferation; Glioma; Humans; Membrane Proteins; Mice; Neoplasm Invasiveness; Nerve Tissue Proteins; Phenoxybenzamine
PubMed: 26409450
DOI: 10.1007/s13277-015-4102-y -
Journal of Pharmaceutical and... Nov 2020The current United States Pharmacopeia-National Formulary (USP-NF) and the British Pharmacopoeia phenoxybenzamine (PBA) hydrochloride drug substance and drug product...
The current United States Pharmacopeia-National Formulary (USP-NF) and the British Pharmacopoeia phenoxybenzamine (PBA) hydrochloride drug substance and drug product monographs describe an HPLC procedure for the determination of a specified impurity "tertiary amine phenoxybenzamine" and use the resolution of an "unknown related substance" from PBA as a system suitability criterion; however, neither structural information of the "unknown related substance" is provided nor reference standards of the two impurities are available. The ambiguity in pharmacopeias poses difficulties in implementing the procedure for quality control. To clarify the degradation pathways, and incorporate the impurity profile of PBA into the USP monographs, the degradation of PBA was revisited. PBA undergoes rapid degradation in neutral or basic aqueous solutions to generate the "tertiary amine phenoxybenzamine" as the predominant degradation product, which was confirmed as phenoxybenzamine hydroxide (PBA-OH). In addition, the "unknown related substance" was proposed as the phenoxybenzamine nitrile (PBA-CN) on the basis of LC-MS studies. The identity of PBA-CN was unambiguously verified via chemical synthesis, HPLC and NMR analyses. A stability-indicating method was developed and validated for the determination of PBA and its impurities, and was used to support USP monograph modernization.
Topics: Chromatography, High Pressure Liquid; Chromatography, Liquid; Drug Contamination; Mass Spectrometry; Phenoxybenzamine
PubMed: 32942108
DOI: 10.1016/j.jpba.2020.113618 -
The Journal of Urology Dec 1976The clinical effect of phenoxybenzamine, an alpha blocking agent, was studied in a series of 37 patients with varying degrees of neurogenic vesical dysfunction. An...
The clinical effect of phenoxybenzamine, an alpha blocking agent, was studied in a series of 37 patients with varying degrees of neurogenic vesical dysfunction. An over-all 78 per cent success rate was achieved, with an 86 per cent success rate in patients with reflex neurogenic bladder. Phenoxybenzamine demonstrates excellent results in patients with neurovesical dysnfunction who are unable to empty their bladders by other means. The drug demonstrated effectiveness regardless of the level of the lesion, cystometric findings or duration of neurogenic vesical disease.
Topics: Adolescent; Adult; Female; Humans; Male; Middle Aged; Phenoxybenzamine; Urinary Bladder, Neurogenic
PubMed: 1003641
DOI: 10.1016/s0022-5347(17)58991-0 -
European Journal of Cardio-thoracic... Apr 2001There is an increasing use of arterial conduits for coronary artery bypass grafting, and the radial artery is commonly used as the third graft. The major drawback of the... (Comparative Study)
Comparative Study
OBJECTIVES
There is an increasing use of arterial conduits for coronary artery bypass grafting, and the radial artery is commonly used as the third graft. The major drawback of the radial artery is its proclivity to spasm. Both papaverine and phenoxybenzamine have been recommended as topical vasodilators in clinical practice. We compared the efficacy of both drugs to prevent radial artery spasm and their ability to preserve endothelial function.
METHODS
The ability of both drugs to prevent alpha-adrenoreceptor mediated constriction was tested in vitro in an organ bath in radial artery segments obtained from 20 patients. Vessel viability was determined by potassium (K(+)) constriction, and endothelial function was assessed by observing endothelium-dependent relaxation by a synthetic analogue of acetylcholine, carbachol.
RESULTS
Papaverine consistently abolished and prevented spasm for up to a maximum of 30 min in all segments. In contrast, phenoxybenzamine consistently abolished and prevented radial artery spasm in all segments for at least 6 h. Whereas papaverine damaged the endothelium of 70% of vessels, there was no evidence of endothelial damage in any arterial segments after exposure to phenoxybenzamine.
CONCLUSIONS
Phenoxybenzamine more effectively prevents alpha-adrenoreceptor mediated spasm of the human radial artery than papaverine. It is also less harmful to the endothelium.
Topics: Adrenergic alpha-Antagonists; Humans; In Vitro Techniques; Papaverine; Phenoxybenzamine; Phosphodiesterase Inhibitors; Radial Artery; Vasodilator Agents; Vasomotor System
PubMed: 11306317
DOI: 10.1016/s1010-7940(01)00598-x -
Urology Dec 1981Phenoxybenzamine (Dibenzyline) has been extremely effective in treating patients with detrusor dyssynergia. Its minimal side effects include: mouth dryness, nasal...
Phenoxybenzamine (Dibenzyline) has been extremely effective in treating patients with detrusor dyssynergia. Its minimal side effects include: mouth dryness, nasal congestion, drowsiness and fatigue, nausea and vomiting, palpitations, ejaculatory failure, and retrograde ejaculation. Nineteen men treated with phenoxybenzamine for detrusor dyssynergia reported ejaculatory failure during treatment; normal ejaculation returned after treatment was discontinued. Postmasturbation urine and semen samples were analyzed for sperm and fructose. The results of the study suggest that ejaculatory failure was due to the lack of seminal emission into the posterior urethra, rather than retrograde ejaculation. Some implications of this study are also discussed.
Topics: Adrenergic alpha-Antagonists; Adult; Ejaculation; Humans; Male; Phenoxybenzamine; Seminal Vesicles; Urinary Bladder, Neurogenic
PubMed: 6118973
DOI: 10.1016/0090-4295(81)90474-x -
Pharmacology, Biochemistry, and Behavior Mar 1981Phenoxybenzamine (10 mg/kg, IP), an alpha-adrenoreceptor blocker, and bromocriptine (5 mg/kg, IP), a dopamine receptor stimulant, were administered to rats while the...
Phenoxybenzamine (10 mg/kg, IP), an alpha-adrenoreceptor blocker, and bromocriptine (5 mg/kg, IP), a dopamine receptor stimulant, were administered to rats while the animals were being deprived of REM sleep by selective REM sleep deprivation method. We have shown recently that alpha-adrenoreceptor blockers and bromocriptine when administered to rats after the animals had been deprived of REM sleep were able to abolish REM sleep rebound and thus attenuate the need for REM sleep. The purpose of this study was to investigate whether these agents might also have the capacity to attenuate the need for REM sleep when given to animals in a situation when the need for REM sleep is being generated, i.e. during REM sleep deprivation. Our results show that administration of phenoxybenzamine or bromocriptine to rats immediately before or during the period of REM sleep deprivation also abolished appearance of subsequent REM sleep rebound. This suggests that administration of the two pharmacological agents prevented the generation of REM sleep pressure by fulfilling the need for REM sleep.
Topics: Animals; Bromocriptine; Male; Phenoxybenzamine; Rats; Sleep; Sleep Deprivation; Sleep, REM; Wakefulness
PubMed: 7232462
DOI: 10.1016/0091-3057(81)90404-4 -
Urology Sep 1975The results of our study show that phenoxybenzamine hydrochloride, a potent long-acting alpha-adrenergic blocker, has clearly demonstrable effects on urethral function....
The results of our study show that phenoxybenzamine hydrochloride, a potent long-acting alpha-adrenergic blocker, has clearly demonstrable effects on urethral function. In a dose of 0.5 mg. per kilogram of body weight it caused a significant lowering of the resting urethral pressure, a decrease in the arterial pressure, and no change in the intravesical pressure. Higher doses caused similar but more pronounced and prolonged effects. The combined use of phenoxybenzamine and bethanechol increased the intravesical pressure and decreased the urethral pressure. It appears that the predominant mechanism of urethral resistance is alpha-adrenergic activity in smooth muscle. A review of the medical literature, our experimental studies, and limited clinical application lead uo to conclude that phenoxybenzamine could be useful in treating neurogenic vesical dysfunction of various types, urethral syndrome, urgency incontinence, functional outlet obstruction with or without vesicoureteral reflux, drug-related obstructive urinary symptoms, partial prostatic obstruction, and ureteral colic. The combination of phenoxybenzamine and bethanechol could be used in managing patients with atony of the bladder of neuropathic or myopathic origin.
Topics: Adult; Animals; Atropine; Bethanechol Compounds; Blood Pressure; Dogs; Drug Interactions; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Phenoxybenzamine; Pressure; Urethra; Urethral Diseases; Urinary Bladder; Urinary Bladder, Neurogenic; Urinary Incontinence, Stress
PubMed: 1167189
DOI: 10.1016/0090-4295(75)90756-6